Cancer Chemotherapy and Pharmacology

Volume 28 1991

Edited by

A. H. CALVERT, M. J. EGORIN, D. R. NEWELL

Editorial Board

P. Alberto Geneva
D. S. Alberts Tucson
M. Boiron Paris
J. Collins Rockville
M. O. Colvin Baltimore
T. Connors Carshalton
R. C. Coombes Sutton
M. d'Incalci Milan
C. Dittrich Vienna
J. H. Doroshow Duarte
S. Eckhardt Budapest
B. W. Fox Manchester
R. M. Fox Victoria
S. Garattini Milano
A. Gouyette Villejuif
H. H. Hansen Copenhagen
A. Jeney Budapest
B. Leyland-Jones Montreal
J. G. McVie London
F. M. Muggia Los Angeles
M. Ogawa Tokyo
W. Plunkett Houston
G. Powis Rochester
M. J. Ratain Chicago
C. G. Schmidt Essen
H. J. Senn St. Gallen
C. Sessa Bellinzona
J. F. Smyth Edinburgh
D. Trump Durham
S. Tsukagoshi Tokyo
T. Tsuruo Tokyo
F. A. Valeriote Detroit
P. M. Wilkinson Manchester
P. Workman Cambridge
G. Wu Huan-Hsin Beijing

Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Founding editor: G. Mathé.
Editors: S. K. Carter, T. J. McElwain. As of volume 23 (1989): S. K. Carter, A. H. Calvert. As of volume 24 (1989): A. H. Calvert, S. K. Carter, M. J. Egorin, and (as of volume 25/1989) D. R. Newell. As of volume 27 (1990) edited by A. H. Calvert, M. J. Egorin, and D. R. Newell.
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page per copy, plus a basic fee of US $ 2.00 per article. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäss bei Augsburg

© Springer-Verlag Berlin Heidelberg 1991

Contents of volume 28

No. 1 (pp 1- 80) published 13 May 1991
No. 2 (pp 81-152) published 5 June 1991
No. 3 (pp 153-234) published 9 July 1991
No. 4 (pp 235-318) published 8 August 1991
No. 5 (pp 319-408) published 11 September 1991
No. 6 (pp 409-490) published 21 October 1991

Aarbakke J → Bremnes RM
Achterrath W → Niederle N
Agata N → Hirano S-I
Airoma G → Gridelli C
Aldhous M → Twelves CJ
Algate DR → Sagrada A
Allan SG, Cummings J, Evans S, Nicolson M, Stewart ME, Cassidy J, Soukop M, Kaye SB, Smyth JF: Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology 55
Allen SG → O'Brien MER
Andersson S-B → Gunnarsson PO
Antman KH → Licht JD
Aonuma M → Kawato Y
Archimbaud E → Salles G
Ardizzoni A → Planting AST
Armus S → Heck DE
Aschan J → Hassan M
Ash CM → Twelves CJ
Ashcroft L → Lind MJ
Azri S → Hagen B

Baguley BC → McKeage MJ
Baguley BC → Ching L-M
Baker MA → Gervasoni JE Jr
Barbosa JL → Weitman SD
Barón-Saura JM → Feliu J
Bartošek I → Guaitani A
Baselga J → Casper ES
Basilico L → Gridelli C
Bastholt L → Jakobsen P
Bastholt L, Johansson C-J, Pfeiffer P, Svensson L, Johansson S-Å, Gunnarsson PO, Mouridsen H: A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients 205
Bastholt L → Jakobsen P
Baumann K → Hannemann J
Beardsley GP → Sokoloski JA
Beckman EM → Muggia FM
Begg AC → Terheggen PMAB
Bekassy AN → Hassan M
Beller U → Muggia FM
Benedetti Panici P → Scambia G
Berens ME → Doz F
Berille J → Fischel JL
Berlion M → Wright M
Berlion M → Fischel JL
Berrocal A → Feliu J
Bhalla K → Gervasoni JE Jr
Bianco AR → Gridelli C
Biard JF → Roussakis C
Bigner DD → Skapek SX
Bisaccia E → Heck DE
Bizzari JP → Wright M
Bizzari JP → Fischel JL
Blaschke G → Boos J
Bleehen NM → Workman P
Bonali P → Sagrada A
Bonanno G → Scambia G
Boos J, Weislau U, Ritter J, Blaschke G, Schellong G: Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children 455
Bower M, Stein RC, Hedley A, Davenport J, Colston K, Coombes RC: The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy 311
Bowman RV, Manning LS, Davis MR, Robinson BWS: Chemosensitivity and cytokine sensitivity of malignant mesothelioma 420
Bremnes RM, Smeland E, Willassen NP, Wist E, Aarbakke J: Inhibition of 7-hydroxymethotrexate formation by amsacrine 377
Bubley G → Teicher BA
Buesa JM, Urréchaga E: Clinical pharmacokinetics of high-dose DTIC 475
Burkhardt A → Mall G

Calvert AH → Jodrell DI
Capelli A → Scambia G
Casper ES, Baselga J, Smart TB, Magill GB, Markman M, Ranhosky A: A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma 51
Cassidy J → Allan SG
Chan KK → Muggia FM
Chan TK → Liang R
Chan TK → Liang R
Chetty U → O'Brien MER
Ching L-M, McKeage MJ, Joseph WR, Kestell P, Zwi LJ, Baguley BC: Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid 414
Chiu E → Liang R
Chiu E → Liang R
Coleman CN → Teicher BA
Colombo N → Muggia FM
Colston K → Bower M
Conley BA, Sewack GF, Egorin MJ, Subramanyam B, Page JG, Grieshaber CK: The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide 33
Coombes RC → Bower M
Corada M → Guaitani A
Coulthard MG → Skinner R
Coustère C, Mentré F, Sommadossi J-P, Diasio RB, Steimer J-L: A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients 123
Craft AW → Skinner R
Crowley JJ → Grunberg SM
Crowther D → Lind MJ
Csuka O → Rakasz E
Cummings J, French RC, MacLellan A, Smyth JF: Chromatographic characterisation of six human metabolites of the new anticancer drug GR63178A 27
Cummings J → Allan SG

Dale O → Hagen B
Dalesio O → Planting AST
Dalmark M → Jakobsen P
Dalmark M → Jakobsen P
Daoud SS, Forde NH: Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells 370
Davenport J → Bower M
Davis MR → Bowman RV
Debitus C → Roussakis C
Denny WA → McKeage MJ
De Placido S → Gridelli C
De Vincenzo R → Scambia G
Dezube B → Teicher BA
Diasio RB → Coustère C
Diedrich H → Freund M
Dobbs NA → Twelves CJ
Donadio M → Giaccone G
Donetti A → Sagrada A
Dopfer R → Ehninger G
Doroshow JH → Vokes EE
Dougherty DV → Doz F
Doz F, Berens ME, Spencer DR, Dougherty DV, Rosenblum ML: Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds 308
Duwe J → Hannemann J

Earl H → Shamash J
Eccles DM → O'Brien MER
Egorin MJ → Conley BA
Ehninger G, Proksch B, Schmidt H, Waidelich P, Eichel B, Dopfer R: Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution 214
Ehrsson H → Hassan M
Eichel B → Ehninger G
Eilam Y → Naftalovich S
Ellman M → Gunnarsson PO
Engelse L den → Terheggen PMAB
Estape J → Planting AST
Evans S → Allan SG

Favalli L → Villani F
Feliu J, Girón CG, González-Baron M, Berrocal A, Barón-Saura JM: Alternating chemotherapy in advanced gastric cancer. A phase II study 313
Ferrandia G → Scambia G
Ferrante G → Gridelli C
Fiere D → Salles G
Fischel JL, Formento P, Berlion M, Berille J, Gioanni J, Bizzari JP, Milano G: Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid 448
FitzGerald GB → Lee M-M
Fleming GF, Vokes EE, McEvilly J-M, Janisch L, Francher D, Smaldone L:

Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis 226
Floot BGJ → Terheggen PMAB
Forde NH → Daoud SS
Formento P → Fischel JL
Francetic DJ → Roberts JC
Francher D → Fleming GF
Frei E III → Teicher BA
Frei E III → Teicher BA
French RC → Cummings J
Freund M, Link H, Diedrich H, LeBlanc S, Wilke H-J, Poliwoda H: High-dose ara-C and etoposide in refractory or relapsing acute leukemia 487
Friedman HS → Skapek SX
Fujimoto S → Nakajima T
Furuta T → Kawato Y

Gaetjens E → Sheid B
Galimberti M → Villani F
Garattini S → Guaitani A
Garès M → Wright M
Garufi C → Gridelli C
Gebbia V → Gridelli C
Geddes D → Twelves CJ
Gentile M → Gridelli C
Gervasoni JE Jr, Taub RN, Rosado M, Krishna S, Stewart VJ, Knowles DM, Bhalla K, Ross DD, Baker MA, Lutzky J, Hindenburg AA: Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells 93
Giaccone G → Planting AST
Giaccone G, Iberti V, Donadio M, Testore F: Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung 147
Gibb I → Skinner R
Gibson W → Jodrell DI
Gioanni J → Fischel JL
Girón CG → Feliu J
Gjedde SB → Jakobsen P
Gjedde SB → Jakobsen P
Goldfinch ME → Skinner R
Goldman J → Twelves CJ
Gomm S → Lind MJ
Gonin R → Licht JD
González-Baron M → Feliu J
Goren MP, Lyman BA, Li JT: The stability of mesna in beverages and syrup for oral administration 298
Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G, Palmieri G, Russo A, Incoronato P, De Placido S, Perrone F, Basilico L, Rausa L, Ferrante G, Bianco AR: Phase II study of Mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer 405
Grieshaber CK → Conley BA
Griffith OW → Skapek SX
Groshen S → Lira-Puerto V
Grunberg SM, Crowley JJ, Livingston RB, Muggia FM, MacDonald JS, Williamson SK, Stephens RL: Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study 211
Guaitani A, Corada M, Lucas C, Lemoine A, Garattini S, Bartošek I: Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma 293
Gunnarsson PO → Bastholt L
Gunnarsson PO, Andersson S-B, Sandberg ÅA, Ellman M: Accumulation of estramustine and estromustine in adipose tissue of rats and humans 361
Gurney H → Lind MJ
Gustafson DL, Pritsos CA: Inhibition of mitomycin C's aerobic toxicity by the seleno-organic antioxidant PZ-51 228

Hagen B, Dale O, Neverdal G, Azri S, Nilsen OG: Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation 441
Hannemann J, Duwe J, Baumann K: Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds 427
Hansen HH → Krarup-Hansen A
Hara Y → Hirano S-I
Harper PC → Twelves CJ
Harper PG → Twelves CJ
Hassan M, Öberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lönnerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B: Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology 130
Heck DE, Bisaccia E, Armus S, Laskin JD: Production of hydrogen peroxide by cutaneous T-cell lymphoma following photopheresis with psoralens and ultraviolet light 344
Hedenus M → Wahlin A
Hedley A → Bower M
Hénichart JP → Mahdadi R
Herman TS → Teicher BA
Herman TS → Teicher BA
Hindenburg AA → Gervasoni JE Jr
Hirano S-I, Agata N, Hara Y, Iguchi H, Shirai M, Tone H, Urakawa N: Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system 266
Hodson AW → Skinner R
Ho F → Liang R
Hoffman R, Newlands ES: Role of protein kinase C in Adriamycin-induced erythroid differentiation of K562 cells 102
Hong WK → Lee JS
Hörnsten P → Wahlin A
Hughes LR → Jodrell DI

Iacobelli S → Gridelli C
Iberti V → Giaccone G
Iguchi H → Hirano S-I
Inaba M → Narita T
Incoronato P → Gridelli C
Isberg B, Paul C, Jönsson L, Svahn U: Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin 171
Israel M → Sweatman TW
Iven H → Kurowski V
Izumisawa Y → Narita T

Jakobsen A → Jakobsen P
Jakobsen A → Sørensen BT
Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT, Jakobsen A: Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer 63
Jakobsen P → Sørensen BT
Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT: A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement 465
Janisch L → Fleming GF
Jansen G, Westerhof GR, Kathmann I, Rijksen G, Schornagel JH: Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds 115
Jeffers S → Muggia FM
Jodrell DI, Newell DR, Gibson W, Hughes LR, Calvert AH: The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats 331
Johansson C-J → Bastholt L
Johansson S-Å → Bastholt L
Jong S de, Zijlstra JG, Mulder NH, Vries EGE de: Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance 461
Jönsson L → Isberg B
Jorgensen TJ → Oudard S
Joseph WR → Ching L-M

Kamen BA → Weitman SD
Kamthan A → Lind MJ
Kathmann I → Jansen G
Kato GJ → Weitman SD
Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice 192
Kaye SB → Allan SG
Kefford R → Rosenthal M
Kenani A → Mahdadi R
Kestell P → McKeage MJ
Kestell P → Ching L-M
Kido Y, Kuwano H, Maehara Y, Mori M, Matsuoka H, Sugimachi K: Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia 251
Kim S → Roy R
Kimura S → Narita T
Kirkpatrick A → Planting AST
Knight G → O'Brien MER
Knowles DM → Gervasoni JE Jr
Koide Y → Narita T
Krarup-Hansen A, Hansen HH: Chemotherapy in malignant mesothelioma: a review 319

Krishna S → Gervasoni JE Jr
Kuppen PJK → Marinelli A
Kurowski V, Iven H: Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice 7
Kuwano H → Kido Y

Lanza E → Villani F
Laskin JD → Heck DE
LeBlanc S → Freund M
Lee JS, Murphy WK, Shirinian MH, Pang A, Hong WK: Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy 199
Lee M-M, Ratliff J, FitzGerald GB, Wick MM: The mechanism of differential sensitivity to methotrexate of normal and malignant human epidermal cells 181
Legrand JJ → Wright M
Leichman L → Muggia FM
Lemoine A → Guaitani A
Lempers ELM → Terheggen PMAB
Lenaz L → Niederle N
Leonard RCF → O'Brien MER
Lerner LM → Sheid B
Lhermitte M → Mahdadi R
Liang R, Chiu E, Chan TK, Todd D: Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia 74
Liang R, Chiu E, Chan TK, Todd D, Ho F: m-BACOD chemotherapy for intermediate- and high-grade non-Hodgkin's lymphoma 135
Licht JD, Gonin R, Antman KH: Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma 223
Li JT → Goren MP
Lind MJ, Gomm S, Simmonds AP, Ashcroft L, Kamthan A, Gurney H, Thatcher N: A phase II study of ifosfamide and a_{2b}-interferon in advanced non-small-cell lung cancer 142
Lind MJ, Murphy DJ, Sharma H, Tinker N, Smith A, McAuliffe CA, Crowther D: Comparative intraperitoneal pharmacokinetics of three platinum analogues 315
Link H → Freund M
Lira-Puerto V, Silva A, Morris M, Martinez R, Groshen S, Morales-Canfield F, Tenorio F, Muggia F: Phase II trial of carboplatin or iproplatin in cervical cancer 391
Livingston RB → Grunberg SM
Ljungman P → Hassan M
Lönnerholm G → Hassan M
Lorenzen A → Jakobsen P
Los G, Verdegaal EME, Mutsaers PHA, McVie JG: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy 159
Lucas C → Guaitani A
Lutzky J → Gervasoni JE Jr
Lyman BA → Goren MP

MacDonald JS → Grunberg SM
MacLellan A → Cummings J
Maehara Y → Kido Y
Magill GB → Casper ES
Mahdadi R, Kenani A, Pommery N, Pommery J, Hénichart JP, Lhermitte M: High-performance liquid chromatography assay of bleomycin in human plasma and rat hepatocytes in culture 22
Mall G, Burkhardt A: Pulmonary toxicity of the combination of bleomycin and peplomycin – an experimental study in rats 357
Malm C → Wahlin A
Mancuso S → Scambia G
Manning LS → Bowman RV
Marinelli A, Pons DHA, Vreeken JAC, Nagesser SK, Kuppen PJK, Tjaden UR, v de Velde CJH: High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats 109
Markman M → Casper ES
Martinez R → Lira-Puerto V
Martin K → Parry H
Masuda H → Nakajima T
Matsumoto K → Kawato Y
Matsuoka H → Kido Y
McAuliffe CA → Lind MJ
McBrien DCH → Mistry P
McEvilly J-M → Fleming GF
McKeage MJ, Kestell P, Denny WA, Baguley BC: Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice 409
McKeage MJ → Ching L-M
McMahon DP → Skapek SX
McVie JG → Planting AST
McVie JG → Los G
Mentré F → Coustère C
Merazga Y → Mistry P
Micheletti R → Sagrada A
Milano G → Fischel JL
Mistry P, Merazga Y, Spargo DJ, Riley PA, McBrien DCH: The effects of cisplatin on the concentration of protein thiols and glutathione in the rat kidney 277
Moisand A → Wright M
Montagna E → Sagrada A
Monti E → Villani F
Morales-Canfield F → Lira-Puerto V
Mori M → Kido Y
Morris M → Lira-Puerto V
Mouridsen H → Bastholt L
Mouridsen HT → Jakobsen P
Mouridsen HT → Jakobsen P
Muggia F → Lira-Puerto V
Muggia FM → Grunberg SM
Muggia FM, Chan KK, Russell C, Colombo N, Speyer JL, Sehgal K, Jeffers S, Sorich J, Leichman L, Beller U, Beckman EM: Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine 241
Mulder NH → Jong S de
Müller MR, Wright KA, Twentyman PR: Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels 273
Murphy DJ → Lind MJ
Murphy WK → Lee JS
Mutsaers PHA → Los G

Naftalovich S, Yefenof E, Eilam Y: Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas 384
Nagesser SK → Marinelli A
Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Fujimoto S, Tsukagoshi S, Taguchi T: Antitumor activity on murine tumors of a novel antitumor benzoylphenylurea derivative, HO-221 351
Narita T, Koide Y, Yaguchi S-I, Kimura S, Izumisawa Y, Takase M, Inaba M, Tsukagoshi S: Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine) 235
Neverdal G → Hagen B
Newell DR → Jodrell DI
Newlands ES → Hoffman R
Newman HFV → Workman P
Nicola M → Sagrada A
Nicolson M → Allan SG
Niederle N, Ostermann J, Achterrath W, Lenaz L, Schmidt CG: Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study 59
Nielsen OS → Jakobsen P
Nielsen OS → Jakobsen P
Nilsen OG → Hagen B

Öberg G → Hassan M
O'Brien MER, Eccles DM, Allen SG, Knight G, Rodger A, Chetty U, Smyth JF, Leonard RCF: Mitozantrone and prednimustine in the treatment of advanced breast cancer – a toxic regimen with low activity 402
Okamoto T → Nakajima T
Ostermann J → Niederle N
Oudard S, Thierry A, Jorgensen TJ, Rahman A: Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes 259

Page JG → Conley BA
Palmeri S → Gridelli C
Palmieri G → Gridelli C
Pang A → Lee JS
Pardee A → Teicher BA
Parker RF → Sweatman TW
Parry H, Martin K: Single-dose i.v. dexamethasone – an effective anti-emetic in cancer chemotherapy 231
Paul C → Isberg B
Pearson ADJ → Skinner R
Pepe R → Gridelli C
Perrone F → Gridelli C
Petersen D → Jakobsen P
Petersen D → Jakobsen P
Pfeiffer P → Bastholt L
Pfeiffer P → Jakobsen P
Piantelli M → Scambia G
Pierelli L → Scambia G
Piloquet P → Roussakis C
Planting AST, Ardizzoni A, Estape J, Giaccone G, Scagliotti G, Splinter TAW,

Kirkpatrick A, Dalesio O, McVie JG: Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872 145
Poggi P → Villani F
Poliwoda H → Freund M
Pommery J → Mahdadi R
Pommery N → Mahdadi R
Pons DHA → Marinelli A
Postels DG → Skapek SX
Pradal G → Roussakis C
Pritsos CA → Gustafson DL
Proksch B → Ehninger G

Raghavan D → Rosenthal M
Rahman A → Oudard S
Rakasz E, Csuka O, Sugar J: Modulation of cytosine arabinoside-induced proliferation inhibition by exogenous adenosylmethionine 484
Ranelletti FO → Scambia G
Ranhosky A → Casper ES
Raschko JW → Vokes EE
Ratain MJ → Vokes EE
Ratliff J → Lee M-M
Rausa L → Gridelli C
Richards MA → Twelves CJ
Rijksen G → Jansen G
Riley PA → Mistry P
Rimoldi EM → Sagrada A
Riou D → Roussakis C
Ritter J → Boos J
Roberts JC, Francetic DJ, Zera RT: L-Cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity 166
Robillard N → Roussakis C
Robinson BWS → Bowman RV
Rodger A → O'Brien MER
Rosado M → Gervasoni JE Jr
Rose C → Jakobsen P
Rose C → Jakobsen P
Rosenblum ML → Doz F
Rosenthal M, Kefford R, Raghavan D, Stuart-Harris R: Epirubicin: A phase II study in recurrent small-cell lung cancer 220
Ross DD → Gervasoni JE Jr
Roussakis C, Robillard N, Riou D, Biard JF, Pradal G, Piloquet P, Debitus C, Verbist JF: Effects of bistramide A on a non-small-cell bronchial carcinoma line 283
Roy R, Kim S: Multivesicular liposomes containing bleomycin for subcutaneous administration 105
Rozza A → Villani F
Rubens RD → Twelves CJ
Russell C → Muggia FM
Russo A → Gridelli C

Saggar M → Sheid B
Sagrada A, Turconi M, Bonali P, Schiantarelli P, Micheletti R, Montagna E, Nicola M, Algate DR, Rimoldi EM, Donetti A: Antiemetic activity of the new 5-HT_3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation 470
Salles G, Archimbaud E, Thomas X, Fiere D: Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy 77
Sandberg ÅA → Gunnarsson PO
Sandberg E → Jakobsen P
Sandberg E → Jakobsen P
Sartorelli AC → Sokoloski JA
Scagliotti G → Planting AST
Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandia G, Pierelli L, Capelli A, Mancuso S: Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites 255
Schellong G → Boos J
Schiantarelli P → Sagrada A
Schilsky RL → Vokes EE
Schmidt CG → Niederle N
Schmidt H → Ehninger G
Schornagel JH → Jansen G
Sehgal K → Muggia FM
Sewack GF → Conley BA
Shamash J, Earl H, Souhami R: Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate 150
Sharma H → Lind MJ
Sheid B, Saggar M, Gaetjens E, Lerner LM: Antiproliferative activity of purine nucleoside dialdehydes against leukemia L1210 in vitro 339
Shirai M → Hirano S-I
Shirinian MH → Lee JS
Shulman L → Teicher BA
Silva A → Lira-Puerto V
Simmonds AP → Lind MJ
Simonsson B → Hassan M
Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS: Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine 15
Skillen AW → Skinner R
Skinner R, Pearson ADJ, Coulthard MG, Skillen AW, Hodson AW, Goldfinch ME, Gibb I, Craft AW: Assessment of chemotherapy-associated nephrotoxicity in children with cancer 81
Smaldone L → Fleming GF
Smart TB → Casper ES
Smedmyr B → Hassan M
Smeland E → Bremnes RM
Smith A → Lind MJ
Smithen CE → Workman P
Smyth JF → Cummings J
Smyth JF → Allan SG
Smyth JF → O'Brien MER
Sokoloski JA, Beardsley GP, Sartorelli AC: Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis 39
Sommadossi J-P → Coustère C
Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A: Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients 397
Sorich J → Muggia FM
Souhami R → Shamash J
Souhami RL → Twelves CJ
Soukop M → Allan SG
Spargo DJ → Mistry P
Spencer DR → Doz F
Speyer JL → Muggia FM
Spiro SG → Twelves CJ
Splinter TAW → Planting AST
Srimuninnimit V, Wampler GL: Case report of metastatic familial phenochromocytoma treated with cisplatin and 5-fluorouracil 217
Steimer J-L → Coustère C
Steiness E → Jakobsen P
Stein RC → Bower M
Stephens RL → Grunberg SM
Stewart ME → Allan SG
Stewart VJ → Gervasoni JE Jr
Strömgren A → Sørensen BT
Stuart-Harris R → Rosenthal M
Subramanyam B → Conley BA
Sugar J → Rakasz E
Sugimachi K → Kido Y
Svahn U → Isberg B
Svensson L → Bastholt L
Sweatman TW, Parker RF, Israel M: Pharmacologic rationale for intravesical *N*-Trifluoroacetyl-adriamycin-14-valerate (AD 32): a preclinical study 1

Taguchi T → Nakajima T
Takase M → Narita T
Tanaka J → Teicher BA
Taube A → Hassan M
Taub RN → Gervasoni JE Jr
Teicher BA, Herman TS, Tanaka J, Dezube B, Pardee A, Frei E III: Fluosol-DA/carbogen with Ionidamine or pentoxifylline as modulators of alkylating agents in the FSallC fibrosarcoma 45
Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei E III: Combination of etanidazole with cyclophosphamide and platinum complexes 153
Tellingen O van → Terheggen PMAB
Tenorio F → Lira-Puerto V
Terheggen PMAB, Floot BGJ, Lempers ELM, Tellingen O van, Begg AC, Engelse L den: Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides 185
Testore F → Giaccone G
Thatcher N → Lind MJ
Thierry A → Oudard S
Thomas X → Salles G
Tinker N → Lind MJ
Tjaden UR → Marinelli A
Tobias JS → Twelves CJ
Todd D → Liang R
Todd D → Liang R
Tone H → Hirano S-I
Tsukagoshi S → Narita T
Tsukagoshi S → Nakajima T
Turconi M → Sagrada A
Twelves CJ, Goldman J, Ash CM, Souhami RL, Harper PC, Spiro SG, Geddes D, Tobias JS: Sequential chemotherapy in good-prognosis patients with small-cell lung cancer 139

Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA: Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer 302
Twentyman PR → Müller MR

Urakawa N → Hirano S-I
Urréchaga E → Buesa JM

VanDellen AF → Skapek SX
v de Velde CJH → Marinelli A
Verbist JF → Roussakis C
Verdegaal EME → Los G
Verdier-Pinard P → Wright M
Villani F, Galimberti M, Zunino F, Monti E, Rozza A, Lanza E, Favalli L, Poggi P: Prevention of Doxorubicin-induced cardiomyopathy by reduced glutathione 365
Vogelzang NJ → Vokes EE
Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL: Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study 69
Vokes EE → Fleming GF
Vreeken JAC → Marinelli A
Vries EGE de → Jong S de

Wahlin A, Hörnsten P, Hedenus M, Malm C: Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia 480
Waidelich P → Ehninger G
Wallin I → Hassan M
Wampler GL → Srimuninnimit V
Ward R → Workman P
Warfield EE → Vokes EE
Watanabe M → Nakajima T
Weislau U → Boos J
Weitman SD, Kato GJ, Barbosa JL, Kamen BA: Low-dose methotrexate therapy for hepatoblastoma 233
Westerhof GR → Jansen G
Wick MM → Lee M-M
Wilke H-J → Freund M
Willassen NP → Bremnes RM
Williamson SK → Grunberg SM
Wist E → Bremnes RM
Workman P, Newman HFV, Bleehen NM, Ward R, Smithen CE: Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man 118
Wright KA → Müller MR
Wright M, Garès M, Verdier-Pinard P, Moisand A, Berlion M, Legrand JJ, Bizzari JP: Differential in vitro action of S-12363, a new vinblastine derivative, and of its epimer on microtubule proteins 434

Yaguchi S-I → Narita T
Yamada N → Nakajima T
Yasuoka M → Kawato Y
Yefenof E → Naftalovich S
Yokokura T → Kawato Y
Yokoyama K → Nakajima T

Zera RT → Roberts JC
Zijlstra JG → Jong S de
Zunino F → Villani F
Zwi LJ → Ching L-M

Indexed in *Current Contents*

Subject index of volume 28

ACNU 145
Acute myeloid leukaemia 74
Adipose tissue 361
Adriamycin 102
Advanced breast cancer 402
Advanced gastric cancer 313
Age 130
Alkylating activity 441
Alprazolam 77
Amsacrine 377
Antagonists 470
Anthracycline resistance 93
Anthrapyrazole biantrazole 55
Antibodies 185
Anti-emetic 231, 470
Antifolate 331
Antileukemic activity 339
Antioxidant 228
Antitumor activity 192, 235, 293, 351, 384
Antitumor agent 409, 414
Arabinoside 74
Ara-C 487
Azathioprine 7

Batanopride 226
BCNU 293
Benzoylphenylurea 351
Bis (2,6-dioxopiperazine) 235
Bistramide A 283
Bleomycin 22, 105, 357
Brain tumor 308
Breast cancer 255, 302
Busulphan 130
Buthionine sulfoximine 15

Calcitonin spray 311
Camptothecin derivative 192
Cancer 81
Canine metabolism 33
Carboplatin 159, 308, 391, 397
Cardiomyopathy 365
Cardiovascular system 266
C1210 cells 339
CCRF-CEM leukemia cells 115
Cervical cancer 391
Chemosensitivity 420
Chemotherapy 81, 139, 147, 199, 217, 231, 313, 319, 470, 480
Children 81, 455
Chlorambucil 205
Chronopharmacology 130
C1941 55
Cisplatin 147, 159, 217, 273, 277, 370, 427
Cisplatin-induced emesis 226
Cisplatin-modified DNA 185
Colon cancer cells 259
Combined chemotherapy regimen 484
CT scan 319
Cutaneous T cell lymphoma 344
Cyclophosphamide 153, 166, 171, 397
L-Cysteine 166
Cytarabine 480
Cytodieresis 283
Cytokines 420
Cytosine 74
Cytosine arabinoside 484
Cytotoxicity 251, 273, 448

Daunorubicin 171, 480
Dexamethasone 231
5,10-Dideazatetrahydrofolic acid 39, 115
Differentiation 39
Dipyridamole 51
Distribution 7
Doxorubicin 302, 365
Drug resistance 461
Drug stability 298

Edatrexate 199
Enantiomers 455
Encapsulation 259
Epidermal cells 181
Epimer 434
Epirubicin 63, 220, 465
Erythroid 102
Estramustine 361
Estrogen receptor 255
Estromustine 361
Etanidazole 153
Etoposide 59, 214, 405, 487